reports
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Ve...
Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026 OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress. The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control,"...
Daxor Corporation to Showcase Next-Generation Portable Blood Volume An...
Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026. Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantificat...
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 ...
Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new, portable blood volume analyzer at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress (Booth #906) at McCormick Place in Chicago, IL, from March 22–24. The new device delivers rapid, lab-quality results making Blood ...
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ide...
Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 Oak Ridge, TN, March 09, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that CEO and President Michael Feldschuh will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026 being held virtually on March 10 -11, 2026. Mr. Feldschuh will deliver a 30-minute presentation on March 10 at 2:00 PM ET, and conduct virtual one-on-one meetings with institutional investors on March 11. Event:iAccess Al...
Daxor Corporation CEO and President Michael Feldschuh Provides Corpora...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. Dear Valued Shareholders, "To measure is to know. If you cannot measure it, you cannot improve it." — Lord Kelvin Lord Kelvin’s timeless scientific principle perfectly encapsulates the miss...
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue ...
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share Strategic Realignment to Clinical Growth Supported by FDA 510(k) Clearance for Next-Generation Blood Volume Analyzer Oak Ridge, TN, March 03, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces financial and operating results for the fiscal year ended December 31, 2025. The company reported a transformative year characterized by significant growth in its operating division and a substantial increase in total ...
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in T...
Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee Expansion Leverages Daxor’s ezBVA Lab to Deliver 98% Accurate Diagnostics with Zero Capital Investment Oak Ridge, TN, Feb. 24, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, continues its strategic expansion into the outpatient cardiology market with the opening of a new BVA program at a leading healthcare facility in Southern Middle Tennessee. This integration brings Daxor’s state-of-the-art testing to a high-volume preventative care setting, driving clinic...
Daxor Corporation Announces Transition To Securities Exchange Act of 1...
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business Oak Ridge, TN, Feb. 10, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announced its intention to transition its primary regulatory reporting framework from the Investment Company Act of 1940 (the Investment Company Act) to the Securities Exchange Act of 1934 (the “Exchange Act”), subject to its completion of required regulatory filings and approvals. This transition re...
Daxor Corporation Announces $9 Million Registered Direct Offering
Daxor Corporation Announces $9 Million Registered Direct Offering OAK RIDGE, TN, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (NasdaqCM: DXR) (“Daxor” or the “Company”) announced today that it has entered into a definitive agreement with fundamental investors for the purchase and sale of an aggregate of 765,958 shares of its common stock (the “Shares”) at a purchase price per Share of $11.75. The offering is expected to close on or about January 26, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the offering to the Company are expected t...
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of...
Daxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer Continued Integration of ezBVA Lab Service and On-Site Analyzer Deployment Signals Accelerating Market Traction Oak Ridge, TN, Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its Blood Volume Analysis (BVA) platform into three new, prestigious facilities. This milestone demonstrates the accelerating market adoption of BVA's pivotal role in precision fluid management, leading to improved patient outcomes ...
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Gro...
Daxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit Summit Features a Select Group of 40 Promising Healthcare Companies at Premier Small-Cap Investor Event OAK RIDGE, TN, Oct. 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that President and Chief Executive Officer Michael Feldschuh will engage institutional investors at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025, at the Hard Rock Hotel in New York City. Mr. Feldschuh will be a...
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum F...
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25 OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall’25 Conference being held at the JW Marriott Austin, from Thursday, October 16 - Saturday, October 18 in Austin, TX. The CV Transforum is the leading conference for cardiovascular organizational performance solutions, uniting industry innovators and thought leaders from across the country. “We are th...
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand a...
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA Three Studies Validate BVA-Guided Care Significantly Cuts Hospital Readmissions and Boosts Survival in High-Cost Heart Failure Segments OAK RIDGE, TN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant commercial momentum and clinical validation following the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The company’s successful debut of its newly FDA-cleared, next-generation BVA a...
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA A...
Daxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer (BVA), signaling a ...
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients ...
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today highlighted the significant findings of a new pilot study published in the Journal of Critical Care. Co-authored by leading intensive care expert...
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global...
Daxor Corporation to Present at the H.C. Wainwright 27th Annual Global Investment Conference Oak Ridge, TN, Sept. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will present at the H.C. Wainwright 27th Annual Global Investment Conference being held on September 8-10, 2025 in New York City at the Lotte New York Palace Hotel. The presentation will be available on-demand beginning Friday, September 5 at 7:00 a.m. ET. Investors who wish to listen to the Company’s presentation can...
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Hal...
Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter Oak Ridge, TN, Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh. Dear Valued Shareholders, "Patience, persistence and perspiration make an unbeatable combination for success." – Napoleon Hill. This timeless wisdom resonates deeply with the journey we've undertaken at Daxor Corporation, and it p...
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now...
Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™. Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Da...
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, B...
Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System Management Expects High Demand Driven by Speed, Simplicity, and Clinical Precision Oak Ridge, TN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces FDA 510(k) clearance (K251087) for its patent-pending next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (BVA). The new Daxor BVA™ device quantifies a patient’s blood volume against patient-specific norms, enabling precise fluid management across a b...
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetratio...
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DXR), the global leader in blood volume measurement technology, announces the expansion of its blood volume analysis (BVA) technology into three new hospitals, a testament to the growing recognition of BVA's essential role in improving lives and reducing healthcare costs. This growth is driven by a combination of Daxor's state-of-t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.